Plasma Replacement Therapy for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease that affects memory, thinking, behavior, and the ability to perform everyday activities. It has been estimated that more than 35 million people worldwide suffered from AD in 2018 , and this figure continues to grow. Unfortunately, no cure or treatment that slows the progression of the disease has been discovered despite extensive efforts from academics and the pharmaceutical industry. Most drug trials for AD have targeted the β-amyloid protein , which accumulates in this disease, and the failure of amyloid-based drugs to impact on cognition in people with AD has led to re-questioning of the amyloid hypothesis of AD, and has provided a fresh impetus to explore alternative therapeutic strategies.
Recently, Sha and colleagues  performed a randomized clinical trial to test the safety, tolerability, and feasibility of weekly administration of young fresh-frozen plasma (yFFP) to treat patients with mild to...
This highlight was supported by the National Natural Science Foundation of China (81722016), and the R&D Infrastructure and Facility Development Program of Sichuan Province, China (2018TJPT0037).
Conflict of interest
The authors declare no conflict of interests.
- 1.Patterson, C. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International 2018.Google Scholar
- 6.Boada M, Anaya F, Ortiz P, Olazaran J, Shua-Haim JR, Obisesan TO, et al. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-beta concentrations and cognition outcomes in Alzheimer’s disease patients: a multicenter, randomized, controlled clinical trial. J Alzheimers Dis 2017, 56: 129–143.CrossRefGoogle Scholar